Literature DB >> 20627931

British Thoracic Society guideline for non-CF bronchiectasis.

M C Pasteur1, D Bilton, A T Hill.   

Abstract

The diagnosis, investigation and particularly management of bronchiectasis has been largely empirical and the subject of relatively few controlled clinical trials. There are no clear guidelines, although an Australian position statement has been published concerning bronchiectasis in children. The purposes of these guidelines were therefore threefold: (1) to identify relevant studies in non-cystic fibrosis (CF) bronchiectasis; (2) to provide guidelines on management based on published studies where possible or a consensus view; and (3) to identify gaps in our knowledge and identify areas for future study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627931     DOI: 10.1136/thx.2010.136119

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  228 in total

1.  Bronchiectasis exacerbations: The role of atypical bacteria, respiratory syncytial virus and pulmonary function tests.

Authors:  Eugenios I Metaxas; Evangelos Balis; Joseph Papaparaskevas; Nicholas Spanakis; Georgios Tatsis; Athanasios Tsakris
Journal:  Can Respir J       Date:  2015-04-15       Impact factor: 2.409

Review 2.  Medical management of bronchiectasis.

Authors:  Anne E O'Donnell
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

3.  Bronchodilator response in adults with bronchiectasis: correlation with clinical parameters and prognostic implications.

Authors:  Wei-Jie Guan; Yong-Hua Gao; Gang Xu; Hui-Min Li; Jing-Jing Yuan; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

Review 4.  Interventions for bronchiectasis: an overview of Cochrane systematic reviews.

Authors:  Emma J Welsh; David J Evans; Stephen J Fowler; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

5.  Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.

Authors:  Emily Henkle; Timothy R Aksamit; Alan F Barker; Jeffrey R Curtis; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Edward Eden; Kevin Fennelly; David E Griffith; Margaret Johnson; Michael R Knowles; Amy Leitman; Philip Leitman; Elisha Malanga; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Delia Prieto; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Susan Wisclenny; Kevin L Winthrop
Journal:  Chest       Date:  2017-05-05       Impact factor: 9.410

Review 6.  Aerosol therapy for obstructive lung diseases: device selection and practice management issues.

Authors:  Michael W Sims
Journal:  Chest       Date:  2011-09       Impact factor: 9.410

Review 7.  Patterns of airway involvement in inflammatory bowel diseases.

Authors:  Ilias Papanikolaou; Konstantinos Kagouridis; Spyros A Papiris
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

8.  Advantages and drawbacks of long-term macrolide use in the treatment of non-cystic fibrosis bronchiectasis.

Authors:  Li-Chao Fan; Jin-Fu Xu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

Review 9.  Pathophysiology and Genetics of Bronchiectasis Unrelated to Cystic Fibrosis.

Authors:  Aleksandra Nikolic
Journal:  Lung       Date:  2018-05-12       Impact factor: 2.584

10.  Neutrophil elastase gene polymorphisms: modulators of response to therapy in childhood bronchiectasis?

Authors:  Aleksandra Nikolic; Katarina Milosevic; Srdjan Boskovic; Branimir Nestorovic
Journal:  Lung       Date:  2014-05-11       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.